By analyzing the processes (cell cycle, inflammation, reactive oxygen species, changes in the p53 pathway) and marker genes (key oncogene MYC, tumor‐associated transcription factors) closely related to tumor progression,[23, 24, 25] we surprisingly found an unexpected enrichment of most of these processes in the group of patients with low CARF expression (Figure S3, Supporting Information). The gene discussed is CARF; the disease is neoplasm.